Research Article
Angiogenesis-Related Biomarkers in Patients with Alcoholic Liver Disease: Their Association with Liver Disease Complications and Outcome
Table 5
Plasma angiogenesis-related biomarkers in subgroups of ALD patients according to the presence of the disease complications.
| | | Ascites | | | | Absent () | Present () | | | Median | 95% CI | 25–75 P | Median | 95% CI | 25–75 P |
| Ang1
ng/mL | 3.19 | 2.32–5.04 | 1.51–5.29 | 2.09 | 1.50–3.17 | 0.16–4.82 | 0.11 |
| Ang2
ng/mL | 3.21 | 2.52–3.88 | 1.88–4.58 | 7.53 | 5.35–9.43 | 3.89–11.40 | <0.0001 |
| VEGF-A
pg/mL | 100.22 | 82.63–196.53 | 61.40–333.36 | 68.73 | 58.66–86.55 | 29.43–149.34 | 0.031 |
| | | Hepatic encephalopathy | | | | Absent () | Present () | | | | Median | 95% CI | 25–75 P | Median | 95% CI | 25–75 P | |
| Ang1
ng/mL | 2.96 | 2.09–3.28 | 1.03–5.70 | 1.77 | 0.00–3.64 | 0.00–3.69 | 0.07 |
| Ang2
ng/mL | 4.45 | 3.64–5.26 | 2.92–8.84 | 10.13 | 5.61–14.87 | 4.83–15.16 | 0.0009 |
| VEGF-A
pg/mL | 91.79 | 71.66–115.74 | 44.30–243.11 | 49.17 | 25.50–84.63 | 25.46–85.27 | 0.003 |
| | | Oesophageal varices | | | | Absent () | Present () | | | | Median | 95% CI | 25–75 P | Median | 95% CI | 25–75 P | |
| Ang1
ng/mL | 3.06 | 2.33–5.14 | 1.75–7.28 | 2.32 | 1.51–3.29 | 0.16–4.70 | 0.08 |
| Ang2
ng/mL | 3.63 | 2.89–5.26 | 1.88–6.21 | 5.12 | 4.37–8.31 | 3.55–11.46 | 0.001 |
| VEGF-A
pg/mL | 100.22 | 72.73–231.94 | 61.98–358.65 | 71.66 | 52.43–89.51 | 26.62–146.57 | 0.005 |
| | | Cholestasis | | | | Absent () | Present () | | | | Median | 95% CI | 25–75 P | Median | 95% CI | 25–75 P | |
| Ang1
ng/mL | 2.32 | 1.51–3.05 | 0.49–5.08 | 4.72 | 3.28–6.40 | 2.90–7.28 | 0.002 |
| Ang2
ng/mL | 4.83 | 3.64–6.55 | 2.90–10.52 | 3.90 | 3.39–4.55 | 3.12–6.21 | 0.28 |
| VEGF-A
pg/mL | 71.81 | 61.40–88.396 | 33.01–168.11 | 121.73 | 101.30–244.22 | 81.52–402.69 | 0.001 |
| | | Renal impairment | | | | Creatinine < 1.3 mg/dL () | Creatinine ≥ 1.3 mg/dL () | | | | Median | 95% CI | 25–75 P | Median | 95% CI | 25–75 P | |
| Ang1
ng/mL | 2.32 | 1.69–3.18 | 0.65–5.29 | 3.27 | 3.05–5.14 | 2.71–5.28 | 0.08 |
| Ang2
ng/mL | 4.45 | 3.63–5.12 | 2.92–9.06 | 9.42 | 7.13–11.40 | 5.09–11.99 | 0.004 |
| VEGF-A
pg/mL | 73.79 | 66.81–91.62 | 33.74–231.66 | 112.68 | 85.52–158.08 | 64.60–207.91 | 0.32 |
| | | Disease outcome | | | | Survivors () | Nonsurvivors () | | | | Median | 95% CI | 25–75 P | Median | 95% CI | 25–75 P | |
| Ang1
ng/mL | 3.05 | 1.98–3.52 | 1.00–5.70 | 2.28 | 0.00–2.71 | 0.00–2.71 | 0.10 |
| Ang2
ng/mL | 4.51 | 3.80–5.26 | 2.92–8.92 | 11.74 | 9.48–13.44 | 9.48–13.44 | 0.001 |
| VEGF-A
pg/mL | 85.270 | 68.73–95.69 | 40.84–207.31 | 73.14 | 25.46–246.83 | 25.46–246.83 | 0.48 |
|
|
